Integra LifeSciences Holdings Co. (NASDAQ:IART) Short Interest Update

Integra LifeSciences Holdings Co. (NASDAQ:IART) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 2,610,000 shares, an increase of 24.9% from the March 31st total of 2,090,000 shares. Based on an average daily volume of 725,500 shares, the short-interest ratio is currently 3.6 days. Currently, 4.0% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Truist Financial decreased their price target on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a research report on Friday, March 1st. StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Tuesday. Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target on the stock in a research note on Wednesday, April 3rd. Finally, JMP Securities reduced their price objective on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research note on Thursday, February 29th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Integra LifeSciences has an average rating of “Hold” and a consensus price target of $44.89.

Institutional Investors Weigh In On Integra LifeSciences

Several large investors have recently made changes to their positions in the company. Signaturefd LLC boosted its holdings in shares of Integra LifeSciences by 248.5% during the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock worth $25,000 after buying an additional 415 shares during the period. Hexagon Capital Partners LLC lifted its holdings in shares of Integra LifeSciences by 123.3% during the 4th quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after acquiring an additional 370 shares during the period. Gladius Capital Management LP acquired a new stake in shares of Integra LifeSciences during the 3rd quarter valued at about $47,000. Valley National Advisers Inc. acquired a new stake in Integra LifeSciences during the first quarter valued at approximately $63,000. Finally, Covestor Ltd lifted its position in shares of Integra LifeSciences by 82.5% during the 3rd quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock worth $78,000 after buying an additional 921 shares during the period. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Down 0.2 %

Shares of NASDAQ IART traded down $0.07 during mid-day trading on Tuesday, reaching $29.17. The company had a trading volume of 650,226 shares, compared to its average volume of 702,239. The stock has a fifty day moving average of $35.02 and a two-hundred day moving average of $38.71. Integra LifeSciences has a 12-month low of $27.18 and a 12-month high of $56.21. The company has a market capitalization of $2.29 billion, a price-to-earnings ratio of 35.14, a PEG ratio of 0.85 and a beta of 1.12. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The company had revenue of $397.00 million for the quarter, compared to analyst estimates of $399.30 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The company’s quarterly revenue was down .3% on a year-over-year basis. During the same period last year, the business earned $0.94 EPS. As a group, equities research analysts expect that Integra LifeSciences will post 3.19 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.